11 September 2023
11 September 2023
Mark Chadwick explains how the EU's new ESG reporting regulation will impact pharmaceutical companies.
Coherus expanded its I-O pipeline by adding clinical-stage antibody immunotherapy candidates of Surface.
Pharmaceutical supply chain partners are trying to create an efficient cold chain system to transport cell and gene therapies.
The funds will be used to progress the Phase II trial of GT101 and next-gen gene-edited tumour-infiltrating lymphocyte products.
In the Phase III THOR study, study subjects in the erdafitinib arm had a median OS of more than one year.
Kroger's settlement, alongside the review of the Purdue Pharma bankruptcy case, is proof that the opioid reckoning isn't over yet.
The company expects a further survival readout in Q4 2023, with plans for a second Phase II trial set for H2 2023.
Eloxx has submitted an IND for a pivotal trial to study its Alport syndrome therapy ELX-02, following a positive Phase II data readout.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
